Cerliponase Alfa
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Cerliponase Alfa: From CLN2 Disease to Scheie Syndrome
One-Sentence Summary
Cerliponase alfa is a recombinant human TPP1 enzyme replacement therapy originally developed for CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2), a lysosomal storage disorder. The TxGNN model predicts it may be effective for Scheie Syndrome (a mild subtype of MPS I), but this direction is currently supported by 0 clinical trials and 0 publications — the prediction stands on model score alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | CLN2 disease (Neuronal Ceroid Lipofuscinosis Type 2) |
| Predicted New Indication | Scheie Syndrome |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| Finland Market Status | ✗ Not Marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available (marked as a Data Gap in the source pack). Based on known information, cerliponase alfa is an enzyme replacement therapy that supplies recombinant tripeptidyl peptidase 1 (TPP1) to treat CLN2 disease, a neurodegenerative lysosomal storage disorder.
Scheie syndrome, however, is a distinct condition — the mild end of the MPS I spectrum, caused by deficiency of α-L-iduronidase, not TPP1. The evidence pack's own repurposing rationale is explicit that there is no direct enzyme-level or biochemical overlap between the two conditions; the only connection is that both fall under the broad umbrella category of "lysosomal storage disease." There is no evidence that TPP1 replacement could substitute for or compensate α-L-iduronidase deficiency.
In short, this prediction reflects a disease-similarity signal from the TxGNN model rather than a mechanistically grounded hypothesis. It should be treated as a hypothesis-generating signal only, not as evidence of therapeutic plausibility.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Safety Considerations
Please refer to the package insert for safety information.
Note: Key TFDA/Fimea package-insert warnings and contraindications data are currently a blocking data gap (DG001) and have not been retrieved; DDI data is also unavailable (query returned not_found).
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted link between cerliponase alfa and Scheie syndrome is supported only by a TxGNN model score (L5 evidence level), with zero clinical trials, zero literature, and an explicitly weak mechanistic rationale (different causative enzyme, no biochemical overlap). This does not meet the threshold to advance beyond model prediction.
To proceed, the following is needed:
- TFDA/Fimea package insert data (warnings, contraindications) — currently a blocking data gap
- Confirmed mechanism of action (MOA) data from DrugBank
- Preclinical or mechanistic studies establishing biological plausibility of TPP1 activity in MPS I/Scheie syndrome
- Any emerging clinical trial or case-report evidence, since none currently exists
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.